摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Ethyl 2,6-di-O-benzyl-4-O-levulinyl-3-O-methyl-1-thio-β-D-glucopyranoside | 202647-37-8

中文名称
——
中文别名
——
英文名称
Ethyl 2,6-di-O-benzyl-4-O-levulinyl-3-O-methyl-1-thio-β-D-glucopyranoside
英文别名
Ethyl 2,6-O-Di-benzyl-4-O-levulinyl-3-O-methyl-1-thio-β-D-glucopyranoside;Bn(-2)[levulinoyl(-4)][Bn(-6)]Glc3Me(b)-SEt;[(2R,3R,4S,5R,6S)-6-ethylsulfanyl-4-methoxy-5-phenylmethoxy-2-(phenylmethoxymethyl)oxan-3-yl] 4-oxopentanoate
Ethyl 2,6-di-O-benzyl-4-O-levulinyl-3-O-methyl-1-thio-β-D-glucopyranoside化学式
CAS
202647-37-8
化学式
C28H36O7S
mdl
——
分子量
516.656
InChiKey
HVWWXOBERKDFFY-IPTPSVHJSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    36
  • 可旋转键数:
    15
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    106
  • 氢给体数:
    0
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    Ethyl 2,6-di-O-benzyl-4-O-levulinyl-3-O-methyl-1-thio-β-D-glucopyranoside 在 (1,5-cyclooctadiene)[bis(methyldiphenylphosphine)]iridium(I) hexafluorophosphate N-碘代丁二酰亚胺三氟甲磺酸 、 4 A molecular sieve 、 氢气 、 mercury dichloride 、 mercury(II) oxide 作用下, 以 四氢呋喃乙醚1,2-二氯乙烷丙酮 为溶剂, 反应 1.25h, 生成 2,6-Di-O-benzyl-4-O-levulinyl-3-O-methyl-α-D-glucopyranosyl-(1->4)-2-O-acetyl-6-O-benzyl-3-O-methyl-Sa-D-glucopyranose
    参考文献:
    名称:
    Experimental Proof for the Structure of a Thrombin-Inhibiting Heparin Molecule
    摘要:
    Kinetic studies of thrombin inhibition by antithrombin in the presence of heparin have shown that thrombin binds to heparin in a preformed heparin - antithrombin complex. To study the relative position of the thrombin binding domain and the antithrombin binding domain on a heparin molecule we have designed and synthesized heparin mimetics which structurally are very similar to the genuine polysaccharide. Their inhibitory properties with respect to factor Xa and thrombin provide experimental evidence that in heparin the thrombin binding domain must be located at the nonreducing end of the antithrombin binding domain to observe thrombin inhibition. As expected, factor Xa inhibition is not affected by elongation of the antithrombin binding pentasaccharide sequence, regardless of the position in which this elongation takes place.
    DOI:
    10.1002/1521-3765(20010216)7:4<858::aid-chem858>3.0.co;2-n
  • 作为产物:
    参考文献:
    名称:
    New synthetic heparin mimetics able to inhibit thrombin and factor Xa
    摘要:
    Synthetic pentadeca-, heptadeca- and nonadecasaccharides, comprising an antithrombin III (AT III) binding pentasaccharide prolonged at the non-reducing end by a thrombin binding domain have been obtained. The pentadecasaccharide is the shortest oligosaccharide able to catalyse thrombin inhibition by AT III. The nonadecasaccharide is a more potent thrombin inhibitor than standard heparin. (C) 1999 Published by Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0960-894x(99)00155-9
点击查看最新优质反应信息

文献信息

  • POLYSACCHARIDES SYNTHETIQUES, PROCEDE POUR LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
    申请人:SANOFI-SYNTHELABO
    公开号:EP0912613B1
    公开(公告)日:2002-09-25
  • US6534481B1
    申请人:——
    公开号:US6534481B1
    公开(公告)日:2003-03-18
  • Experimental Proof for the Structure of a Thrombin-Inhibiting Heparin Molecule
    作者:Maurice Petitou、Anne Imberty、Philippe Duchaussoy、Pierre-Alexandre Driguez、Marie-Line Ceccato、Françoise Gourvenec、Philippe Sizun、Jean-Pascal Hérault、Serge Pérez、Jean-Marc Herbert
    DOI:10.1002/1521-3765(20010216)7:4<858::aid-chem858>3.0.co;2-n
    日期:2001.2.16
    Kinetic studies of thrombin inhibition by antithrombin in the presence of heparin have shown that thrombin binds to heparin in a preformed heparin - antithrombin complex. To study the relative position of the thrombin binding domain and the antithrombin binding domain on a heparin molecule we have designed and synthesized heparin mimetics which structurally are very similar to the genuine polysaccharide. Their inhibitory properties with respect to factor Xa and thrombin provide experimental evidence that in heparin the thrombin binding domain must be located at the nonreducing end of the antithrombin binding domain to observe thrombin inhibition. As expected, factor Xa inhibition is not affected by elongation of the antithrombin binding pentasaccharide sequence, regardless of the position in which this elongation takes place.
  • New synthetic heparin mimetics able to inhibit thrombin and factor Xa
    作者:Maurice Petitou、Philippe Duchaussoy、Pierre-A. Driguez、Jean-P. Hérault、Jean-C. Lormeau、Jean-M. Herbert
    DOI:10.1016/s0960-894x(99)00155-9
    日期:1999.4
    Synthetic pentadeca-, heptadeca- and nonadecasaccharides, comprising an antithrombin III (AT III) binding pentasaccharide prolonged at the non-reducing end by a thrombin binding domain have been obtained. The pentadecasaccharide is the shortest oligosaccharide able to catalyse thrombin inhibition by AT III. The nonadecasaccharide is a more potent thrombin inhibitor than standard heparin. (C) 1999 Published by Elsevier Science Ltd. All rights reserved.
查看更多